Medidata (NASDAQ: MDSO) today announced that medical technology business Smith & Nephew (LSE: SN, NYSE: SNN) has consolidated all of its global studies on the Medidata Rave Clinical Cloud. The company expanded its use of Rave clinical solutions and will leverage...
3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) in patients...
Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from a Phase 1 study of its novel...
Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee (“TSC”) reviewed safety data from the...
NIH-funded clinical trial finds starting treatment prior to vision loss unnecessary for most people; close monitoring essential. People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition...
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have been awarded a $4.6 million grant from the California Institute for Regenerative Medicine – also known as CIRM – to support a phase I clinical trial of...
Email
Text